{"transactions":[{"id":4616596,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:03.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":2244640,"source":{"system":"sec-edgar","filing":"0001193125-26-389887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897557/000119312526389887/ownership.xml","form_type":"4"}},{"id":5104,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-09-05T01:30:03.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":19023,"price":37.94,"value":721732.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 3, 2026 at prices ranging from $37.46 to $38.94. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1494640,"source":{"system":"sec-edgar","filing":"0001193125-26-384042","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1897557/000119312526384042/ownership.xml","form_type":"4"}},{"id":5103,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-09-05T01:30:03.000Z","date":"2026-09-02","kind":"grant","planned":true,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective February 3, 2026.  Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026."}],"balance_after":1513663,"source":{"system":"sec-edgar","filing":"0001193125-26-384042","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897557/000119312526384042/ownership.xml","form_type":"4"}},{"id":689333,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:10.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":1473246,"source":{"system":"sec-edgar","filing":"0001193125-26-345839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345839/ownership.xml","form_type":"4"}},{"id":725563,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:05.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":29208,"price":45.03,"value":1315236.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."}],"balance_after":1098246,"source":{"system":"sec-edgar","filing":"0001193125-26-285562","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285562/ownership.xml","form_type":"4"}},{"id":730573,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:05.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":1127454,"source":{"system":"sec-edgar","filing":"0001193125-26-276882","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276882/ownership.xml","form_type":"4"}},{"id":827416,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-03-26T22:42:23.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":24431,"price":18.47,"value":451240.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan."}],"balance_after":752454,"source":{"system":"sec-edgar","filing":"0001193125-26-126825","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526126825/ownership.xml","form_type":"4"}},{"id":917822,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-02-05T21:53:18.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":1098477,"source":{"system":"sec-edgar","filing":"0001193125-26-039571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039571/ownership.xml","form_type":"4"}},{"id":958268,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-12-29T22:00:06.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":25791,"price":13.1469,"value":339071.6979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":778477,"source":{"system":"sec-edgar","filing":"0001193125-25-335483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525335483/ownership.xml","form_type":"4"}},{"id":1031771,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-09-26T21:35:13.000Z","date":"2025-09-25","kind":"sale","planned":true,"acquired":false,"shares":25797,"price":9.77,"value":252036.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."}],"balance_after":804268,"source":{"system":"sec-edgar","filing":"0001193125-25-220847","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525220847/ownership.xml","form_type":"4"}},{"id":1101105,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-06-26T20:30:04.000Z","date":"2025-06-25","kind":"sale","planned":true,"acquired":false,"shares":26491,"price":6.8,"value":180138.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":830065,"source":{"system":"sec-edgar","filing":"0000950170-25-090428","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025090428/ownership.xml","form_type":"4"}},{"id":1191013,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-03-26T21:00:18.000Z","date":"2025-03-25","kind":"sale","planned":true,"acquired":false,"shares":21208,"price":6.74,"value":142941.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":856556,"source":{"system":"sec-edgar","filing":"0000950170-25-045397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025045397/ownership.xml","form_type":"4"}},{"id":1207875,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-03-13T20:30:13.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 1,098 shares acquired under the Mind Medicine (MindMed) Inc. 2024 Employee Share Purchase Plan on February 18, 2025."}],"balance_after":877764,"source":{"system":"sec-edgar","filing":"0000950170-25-038801","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025038801/ownership.xml","form_type":"4"}},{"id":1321007,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-12-27T21:31:46.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":19106,"price":7.43,"value":141957.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":526666,"source":{"system":"sec-edgar","filing":"0001104659-24-132167","document":"tm2432133-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465924132167/tm2432133-4_4seq1.xml","form_type":"4"}},{"id":1399511,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-09-26T00:29:51.000Z","date":"2024-09-25","kind":"sale","planned":true,"acquired":false,"shares":19771,"price":5.98,"value":118230.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":545772,"source":{"system":"sec-edgar","filing":"0000950170-24-109449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024109449/ownership.xml","form_type":"4"}},{"id":1427780,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-08-21T01:14:04.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":6.12,"value":3060.0,"ownership":{"direct":true},"balance_after":565543,"source":{"system":"sec-edgar","filing":"0000950170-24-099351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024099351/ownership.xml","form_type":"4"}},{"id":1427779,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-08-21T01:14:04.000Z","date":"2024-08-19","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":6.31,"value":3155.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions on August 19, 2024, at prices ranging from $6.29 to $6.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":565043,"source":{"system":"sec-edgar","filing":"0000950170-24-099351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024099351/ownership.xml","form_type":"4"}},{"id":1469589,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-06-25T23:00:03.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":15659,"price":7.22,"value":113057.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":564543,"source":{"system":"sec-edgar","filing":"0000950170-24-077495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024077495/ownership.xml","form_type":"4"}},{"id":1560690,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-03-26T21:15:08.000Z","date":"2024-03-25","kind":"sale","planned":true,"acquired":false,"shares":16519,"price":9.5,"value":156930.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2024 at prices ranging from $9.37 to $9.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":580202,"source":{"system":"sec-edgar","filing":"0000950170-24-036572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024036572/ownership.xml","form_type":"4"}},{"id":1610170,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:16.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":400000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-24-023202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023202/ownership.xml","form_type":"4"}},{"id":1700174,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-12-26T21:50:28.000Z","date":"2023-12-26","kind":"sale","planned":false,"acquired":false,"shares":13237,"price":3.63,"value":48050.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2023 at prices ranging from $3.60 to $3.67 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":596721,"source":{"system":"sec-edgar","filing":"0000950170-23-073069","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023073069/ownership.xml","form_type":"4"}},{"id":1773998,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-09-26T01:30:10.000Z","date":"2023-09-25","kind":"sale","planned":false,"acquired":false,"shares":8231,"price":3.58,"value":29466.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $3.57 to $3.60 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":611729,"source":{"system":"sec-edgar","filing":"0000950170-23-049779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023049779/ownership.xml","form_type":"4"}},{"id":1773997,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-09-26T01:30:10.000Z","date":"2023-09-25","kind":"sale","planned":false,"acquired":false,"shares":5268,"price":3.57,"value":18806.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on September 25, 2023. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $4.78 to $4.84 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":619960,"source":{"system":"sec-edgar","filing":"0000950170-23-049779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023049779/ownership.xml","form_type":"4"}},{"id":1843528,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-06-27T23:41:45.000Z","date":"2023-06-27","kind":"sale","planned":false,"acquired":false,"shares":8416,"price":3.21,"value":27015.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $3.20 to $3.23 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":623457,"source":{"system":"sec-edgar","filing":"0000950170-23-030256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023030256/ownership.xml","form_type":"4"}},{"id":1843527,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-06-27T23:41:45.000Z","date":"2023-06-27","kind":"sale","planned":false,"acquired":false,"shares":7086,"price":3.19,"value":22604.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on June 27, 2023. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $4.20 to $4.23 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":631873,"source":{"system":"sec-edgar","filing":"0000950170-23-030256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023030256/ownership.xml","form_type":"4"}},{"id":1947289,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-03-17T22:41:34.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":638959,"source":{"system":"sec-edgar","filing":"0001209191-23-019896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919123019896/doc4.xml","form_type":"4"}},{"id":1979873,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-03-03T02:43:46.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":8273,"price":3.51,"value":29038.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on March 1, 2023. These shares were sold in multiple transactions on March 1, 2023 at prices ranging from $4.75 to $4.80 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":238959,"source":{"system":"sec-edgar","filing":"0000899243-23-006786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924323006786/doc4.xml","form_type":"4"}},{"id":2077728,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-12-22T21:37:48.000Z","date":"2022-12-21","kind":"sale","acquired":false,"shares":3861,"price":2.69,"value":10386.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on November 15, 2022,  November 24, 2022, and December 15, 2022, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on December 21, 2022. These shares were sold in multiple transactions on December 21, 2022 at prices ranging from $3.65 to $3.67 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":247232,"source":{"system":"sec-edgar","filing":"0000899243-22-039214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322039214/doc4.xml","form_type":"4"}},{"id":2132400,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-10-25T21:57:38.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":1207,"price":2.81,"value":3391.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on October 24, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in multiple transactions, all at a price of $3.83 CAD Dollars. This represents the price in United States Dollars using the conversion rate on October 25, 2022."}],"balance_after":251093,"source":{"system":"sec-edgar","filing":"0000899243-22-034146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322034146/doc4.xml","form_type":"4"}},{"id":2135628,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-10-18T20:34:45.000Z","date":"2022-10-18","kind":"sale","acquired":false,"shares":1220,"price":3.11,"value":3794.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on October 15, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $4.28 CAD Dollars. This represents the price in United States Dollars using the conversion rate on October 18, 2022."}],"balance_after":252300,"source":{"system":"sec-edgar","filing":"0000899243-22-033749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322033749/doc4.xml","form_type":"4"}},{"id":2150584,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-09-27T22:39:43.000Z","date":"2022-09-26","kind":"sale","acquired":false,"shares":1264,"price":5.51,"value":6964.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on September 24, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $7.60 CAD Dollars. This represents the price in United States Dollars using the conversion rate on September 26, 2022."}],"balance_after":253520,"source":{"system":"sec-edgar","filing":"0000899243-22-032164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322032164/doc4.xml","form_type":"4"}},{"id":2155881,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-09-19T16:58:00.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":1350,"price":7.26,"value":9801.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on September 15, 2022 pursuant to sell-to-cover elections"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $9.65 CAD Dollars. This represents the price in United States Dollars using the conversion rate on September 16, 2022."}],"balance_after":254784,"source":{"system":"sec-edgar","filing":"0000899243-22-031430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322031430/doc4.xml","form_type":"4"}},{"id":2169076,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-09-01T16:16:47.000Z","date":"2022-08-31","kind":"sale","acquired":false,"shares":1228,"price":11.67,"value":14330.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on August 24, 2022 pursuant to sell-to-cover elections"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $15.31 CAD Dollars. This represents the price in United States Dollars using the conversion rate on August 31, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the\" Reverse Stock Split\"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":256134,"source":{"system":"sec-edgar","filing":"0000899243-22-030156","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322030156/doc4.xml","form_type":"4"}},{"id":2181961,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-08-17T22:36:48.000Z","date":"2022-08-16","kind":"sale","acquired":false,"shares":20350,"price":0.68,"value":13838.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on August 15, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $0.87 CAD Dollars. This represents the price in United States Dollars using the conversion rate on August 16, 2022."}],"balance_after":3860438,"source":{"system":"sec-edgar","filing":"0000899243-22-029072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322029072/doc4.xml","form_type":"4"}},{"id":2201831,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-07-26T17:23:06.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":18681,"price":0.69,"value":12889.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on July 24, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $0.88 CAD Dollars. This represents the price in United States Dollars using the conversion rate on July 25, 2022."}],"balance_after":3880788,"source":{"system":"sec-edgar","filing":"0000899243-22-026724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322026724/doc4.xml","form_type":"4"}},{"id":2206344,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-07-18T22:35:02.000Z","date":"2022-07-18","kind":"sale","acquired":false,"shares":19388,"price":0.7,"value":13571.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on July 15, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $0.90 CAD Dollars. This represents the price in United States Dollars using the conversion rate on July 18, 2022."}],"balance_after":3899469,"source":{"system":"sec-edgar","filing":"0000899243-22-026255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322026255/doc4.xml","form_type":"4"}},{"id":2220282,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-06-28T22:05:23.000Z","date":"2022-06-27","kind":"sale","acquired":false,"shares":36762,"price":0.7,"value":25733.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on June 24, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $0.90 CAD Dollars. This represents the price in United States Dollars using the conversion rate on June 27, 2022."}],"balance_after":3918857,"source":{"system":"sec-edgar","filing":"0000899243-22-024435","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322024435/doc4.xml","form_type":"4"}},{"id":2225703,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-06-21T21:12:24.000Z","date":"2022-06-16","kind":"sale","acquired":false,"shares":21275,"price":0.7,"value":14892.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on June 15, 2022 pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Shares were sold in one transaction at a price of $0.91 CAD Dollars. This represents the price in United States Dollars using the conversion rate on June 16, 2022."}],"balance_after":3955619,"source":{"system":"sec-edgar","filing":"0001209191-22-038480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122038480/doc4.xml","form_type":"4"}},{"id":2255389,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-05-27T01:09:21.000Z","date":"2022-05-25","kind":"sale","acquired":false,"shares":18415,"price":0.77,"value":14179.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Subordinate Voting Shares sold to satisfy withholding tax obligations upon the delivery of Subordinate Voting Shares for restricted stock units that vested on May 24, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Subordinate Voting Shares were sold in one transaction at a price of $0.99 CAD Dollars. This represents the price in United States Dollars using the conversion rate on May 25, 2022."}],"balance_after":3976894,"source":{"system":"sec-edgar","filing":"0001209191-22-032383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122032383/doc4.xml","form_type":"4"}},{"id":2263939,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-05-19T20:16:31.000Z","date":"2022-05-18","kind":"sale","acquired":false,"shares":18948,"price":0.71,"value":13453.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Subordinate Voting Shares sold to satisfy withholding tax obligations upon the delivery of Subordinate Voting Shares for restricted stock units that vested on May 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Subordinate Voting Shares were sold in one transaction at a price of $0.92 CAD Dollars. This represents the price in United States Dollars using the conversion rate on May 18, 2022."}],"balance_after":3995309,"source":{"system":"sec-edgar","filing":"0001209191-22-030499","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122030499/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-17"}},{"id":2268323,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-05-18T01:34:07.000Z","date":"2022-05-15","kind":"tax_withholding","acquired":false,"shares":18948,"price":0.82,"value":15537.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,313 restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The closing price of our Subordinate Voting Shares as of May 13, 2022 on the NEO was $1.00 Canadian Dollars. This represents the price in United States Dollars."}],"balance_after":3995309,"source":{"system":"sec-edgar","filing":"0001209191-22-029901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122029901/doc4.xml","form_type":"4"}},{"id":2294872,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-04-19T23:18:34.000Z","date":"2022-04-18","kind":"tax_withholding","acquired":false,"shares":19110,"price":0.92,"value":17581.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,312 restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The closing price of our Subordinate Voting Shares as of April 18, 2022 on the NEO was $1.16 Canadian Dollars. This represents the price in United States Dollars."}],"balance_after":4014257,"source":{"system":"sec-edgar","filing":"0001209191-22-024842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122024842/doc4.xml","form_type":"4"}},{"id":2316726,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-29T00:03:28.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":2910000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest and become exercisable with 1/48th of the total shares vesting monthly over 48 months from the vesting commencement date, March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":6425500,"derivative":{"exercise_price":1.18,"expiration_date":"2027-03-23","underlying":"Subordinate Voting Shares","underlying_shares":2910000},"source":{"system":"sec-edgar","filing":"0001209191-22-021385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122021385/doc4.xml","form_type":"4"}},{"id":2316725,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-03-29T00:03:28.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":1820000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in 48 equal monthly installments beginning on April 24, 2022, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":4033367,"source":{"system":"sec-edgar","filing":"0001209191-22-021385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122021385/doc4.xml","form_type":"4"}},{"id":2327857,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-03-17T23:26:13.000Z","date":"2022-03-15","kind":"tax_withholding","acquired":false,"shares":12612,"price":1,"value":12612.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,312 restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The closing price of our Subordinate Voting Shares as of March 15, 2022 on the NEO was $1.28 Canadian Dollars. This represents the price in United States Dollars."}],"balance_after":2213367,"source":{"system":"sec-edgar","filing":"0001209191-22-019815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122019815/doc4.xml","form_type":"4"}},{"id":2388793,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-02-18T02:16:08.000Z","date":"2022-02-15","kind":"tax_withholding","acquired":false,"shares":18734,"price":1.35,"value":25290.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,313 restricted stock units."}],"balance_after":2225979,"source":{"system":"sec-edgar","filing":"0001209191-22-011077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122011077/doc4.xml","form_type":"4"}},{"id":2432423,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subordinate Voting Shares","published_at":"2022-01-20T00:14:57.000Z","date":"2022-01-15","kind":"tax_withholding","acquired":false,"shares":190287,"price":1.05,"value":199801.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 608,750 restricted stock units."}],"balance_after":2244713,"source":{"system":"sec-edgar","filing":"0001209191-22-003854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122003854/doc4.xml","form_type":"4"}}]}